We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. From: Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing.

Working model for specific human leukocyte antigen (HLA)-B molecule interacting with a drug compound. HLA-B molecules present endogenous or processed exogenous antigens to T cells, thereby eliciting an adaptive immune response. The T-cell receptor of the effector T cell recognizes the drug–peptide complex bound by the specific HLA-B molecule on the antigen-presenting cell, resulting in the release of immune mediators.

M S Hershfield, et al. Clin Pharmacol Ther. 2013 February;93(2):153-158.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk